Histone deacetylase knockouts modify transcription, CAG instability and nuclear pathology in Huntington disease mice

  1. Marina Kovalenko
  2. Serkan Erdin
  3. Marissa A Andrew
  4. Jason St Claire
  5. Melissa Shaughnessey
  6. Leroy Hubert
  7. João Luís Neto
  8. Alexei Stortchevoi
  9. Daniel M Fass
  10. Ricardo Mouro Pinto
  11. Stephen J Haggarty
  12. John H Wilson
  13. Michael E Talkowski
  14. Vanessa C Wheeler  Is a corresponding author
  1. Massachusetts General Hospital, United States
  2. Massachusetts General Hospital/Broad Institute, United States
  3. Baylor College of Medicine, United States
  4. Massachusetts General Hospital, Harvard Medical School, United States

Abstract

Somatic expansion of the Huntington's disease (HD) CAG repeat drives the rate of a pathogenic process ultimately resulting in neuronal cell death. Although mechanisms of toxicity are poorly delineated, transcriptional dysregulation is a likely contributor. To identify modifiers that act at the level of CAG expansion and/or downstream pathogenic processes, we tested the impact of genetic knockout, in HttQ111 mice, of Hdac2 or Hdac3 in medium-spiny striatal neurons that exhibit extensive CAG expansion and exquisite disease vulnerability. Both knockouts moderately attenuated CAG expansion, with Hdac2 knockout decreasing nuclear huntingtin pathology. Hdac2 knockout resulted in a substantial transcriptional response that included modification of transcriptional dysregulation elicited by the HttQ111 allele, likely via mechanisms unrelated to instability suppression. Our results identify novel modifiers of different aspects of HD pathogenesis in MSNs and highlight a complex relationship between the expanded Htt allele and Hdac2 with implications for targeting transcriptional dysregulation in HD.

Data availability

RNA-Seq data is deposited in GEO, under the accession number GSE148440

The following data sets were generated

Article and author information

Author details

  1. Marina Kovalenko

    Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  2. Serkan Erdin

    Center for Genomic Medicine/Program in Medical and Population Genetics, Massachusetts General Hospital/Broad Institute, Boston, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6587-2625
  3. Marissa A Andrew

    Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  4. Jason St Claire

    Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  5. Melissa Shaughnessey

    Center for Genomic Medicine; Department of Neurology, Massachusetts General Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  6. Leroy Hubert

    Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, United States
    Competing interests
    No competing interests declared.
  7. João Luís Neto

    Center for Genomic Medicine; Department of Neurology, Massachusetts General Hospital, Boston, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0863-158X
  8. Alexei Stortchevoi

    Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  9. Daniel M Fass

    Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
    Competing interests
    Daniel M Fass, D.M.F. is a member of the scientific advisory board of Psy Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0018-8093
  10. Ricardo Mouro Pinto

    Center for Genomic Medicine; Department of Neurology, Massachusetts General Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  11. Stephen J Haggarty

    Chemical Neurobiology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, United States
    Competing interests
    Stephen J Haggarty, S.J.H. is a member of the scientific advisory board of Psy Therapeutics, Frequency Therapeutics and Souvien Therapeutics, and former member of the scientific advisory board of Rodin Therapeutics that is focused on HDAC2 inhibitors, none of whom were involved in the present study. S.J.H. has also received speaking or consulting fees from Amgen, AstraZeneca, Biogen, Merck, Regenacy Pharmaceuticals, as well as sponsored research or gift funding from AstraZeneca, JW Pharmaceuticals, and Vesigen unrelated to the content of this manuscript. His financial interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7872-168X
  12. John H Wilson

    Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, United States
    Competing interests
    No competing interests declared.
  13. Michael E Talkowski

    Center for Genomic Medicine/Program in Medical and Population Genetics, Massachusetts General Hospital/Broad Institute, Boston, United States
    Competing interests
    No competing interests declared.
  14. Vanessa C Wheeler

    Center for Genomic Medicine; Department of Neurology, Massachusetts General Hospital, Boston, United States
    For correspondence
    wheeler@helix.mgh.harvard.edu
    Competing interests
    Vanessa C Wheeler, V.C.W is a scientific advisory board member of Triplet Therapeutics, a company developing new therapeutic approaches to address triplet repeat disorders such Huntington's disease and Myotonic Dystrophy and of LoQus23 Therapeutics. Her financial interests in Triplet Therapeutics, were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2619-589X

Funding

Huntington Society of Canada (New Pathways Research Grant)

  • Vanessa C Wheeler

National Institutes of Health (NS049206)

  • Vanessa C Wheeler

Huntington's Disease Society of America (Berman Topper Career Development Award)

  • Ricardo Mouro Pinto

National Institutes of Health (GM38219)

  • John H Wilson

National Institutes of Health (EY11731)

  • John H Wilson

National Institutes of Health (1F3HG004918)

  • Leroy Hubert

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health under an approved protocol (2009N000216) of the Massachusetts General Hospital Subcommittee on Research Animal Care.

Copyright

© 2020, Kovalenko et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,159
    views
  • 303
    downloads
  • 8
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Marina Kovalenko
  2. Serkan Erdin
  3. Marissa A Andrew
  4. Jason St Claire
  5. Melissa Shaughnessey
  6. Leroy Hubert
  7. João Luís Neto
  8. Alexei Stortchevoi
  9. Daniel M Fass
  10. Ricardo Mouro Pinto
  11. Stephen J Haggarty
  12. John H Wilson
  13. Michael E Talkowski
  14. Vanessa C Wheeler
(2020)
Histone deacetylase knockouts modify transcription, CAG instability and nuclear pathology in Huntington disease mice
eLife 9:e55911.
https://doi.org/10.7554/eLife.55911

Share this article

https://doi.org/10.7554/eLife.55911

Further reading

    1. Evolutionary Biology
    2. Genetics and Genomics
    Philipp H Schiffer, Paschalis Natsidis ... Maximilian J Telford
    Research Article Updated

    The evolutionary origins of Bilateria remain enigmatic. One of the more enduring proposals highlights similarities between a cnidarian-like planula larva and simple acoel-like flatworms. This idea is based in part on the view of the Xenacoelomorpha as an outgroup to all other bilaterians which are themselves designated the Nephrozoa (protostomes and deuterostomes). Genome data can provide important comparative data and help understand the evolution and biology of enigmatic species better. Here, we assemble and analyze the genome of the simple, marine xenacoelomorph Xenoturbella bocki, a key species for our understanding of early bilaterian evolution. Our highly contiguous genome assembly of X. bocki has a size of ~111 Mbp in 18 chromosome-like scaffolds, with repeat content and intron, exon, and intergenic space comparable to other bilaterian invertebrates. We find X. bocki to have a similar number of genes to other bilaterians and to have retained ancestral metazoan synteny. Key bilaterian signaling pathways are also largely complete and most bilaterian miRNAs are present. Overall, we conclude that X. bocki has a complex genome typical of bilaterians, which does not reflect the apparent simplicity of its body plan that has been so important to proposals that the Xenacoelomorpha are the simple sister group of the rest of the Bilateria.

    1. Evolutionary Biology
    2. Genetics and Genomics
    Akiko Satake, Ryosuke Imai ... Masahiro Kasahara
    Research Article

    The rates of appearance of new mutations play a central role in evolution. However, mutational processes in natural environments and their relationship with growth rates are largely unknown, particular in tropical ecosystems with high biodiversity. Here, we examined the somatic mutation landscapes of two tropical trees, Shorea laevis (slow-growing) and S. leprosula (fast-growing), in central Borneo, Indonesia. Using newly constructed genomes, we identified a greater number of somatic mutations in tropical trees than in temperate trees. In both species, we observed a linear increase in the number of somatic mutations with physical distance between branches. However, we found that the rate of somatic mutation accumulation per meter of growth was 3.7-fold higher in S. laevis than in S. leprosula. This difference in the somatic mutation rate was scaled with the slower growth rate of S. laevis compared to S. leprosula, resulting in a constant somatic mutation rate per year between the two species. We also found that somatic mutations are neutral within an individual, but those mutations transmitted to the next generation are subject to purifying selection. These findings suggest that somatic mutations accumulate with absolute time and older trees have a greater contribution towards generating genetic variation.